A new @science.org study shows that the time of antigen exposure influences how dendritic cells program CD8⁺ T-cell memory through their intrinsic circadian clock, with important implications for vaccination and immunotherapy. Link in the comments 👇

Can a single CAR T-cell infusion lead to decade-long remission in B-cell lymphoma? A new @nejm.org study reports some of the longest follow-up data available for anti-CD19 CAR T-cell therapy. Link in the comments 👇 #Oncology #CARTcell #CellTherapy

Huge congratulations to Dr. Andy on graduating with his PhD! 🎓 We wish you the absolute best in your next chapter, Dr. Andy!

A recent Nature study reveals that prior chemotherapy and radiation do not simply kill cancer cells — they leave distinct, measurable mutational scars that actively shape tumor evolution at relapse. Link in the comments 👇 #ChildhoodCancer #NatureResearch #CancerGenomics

Can pancreatic cancer be intercepted before it develops? Most pancreatic cancers begin with KRAS mutations, often years before an invasive tumor appears. Link in the comments 👇 #PancreaticCancer #KRAS #CancerVaccines #CancerPrevention #Immunotherapy #ClinicalTrials

#LabLife Lab meetings in progress! A quick hello from our team! We hope you all have a wonderful weekend filled with good company and inspiration. See you next week! ✨

Can ferroptosis make cancer vaccines more effective? A recent study in @nature.com offers a clever workaround: pre-treating tumor cells with ferroptosis before using their lysates to load DCs. Link in the comments 👇 #CancerResearch #Immunotherapy

Is targeted protein degradation ready to compete with established cancer therapies? The latest Phase 3 data suggest the answer may be yes. Results from the SUCCESSOR-2 trial have put mezigdomide in the spotlight. Article link 👇 #MultipleMyeloma #Oncology #ClinicalTrials

#LabLife It was a pleasure meeting Prof. Edmond Kam-lun Lau from Hong Kong Shue Yan University (HKSYU). We are excited to bring together expertise in forensic chemistry and criminal psychology to develop new interdisciplinary teaching and future courses.

The phase 2 POLAR trial, published in @naturemedicine.bsky.social evaluated maintenance pembrolizumab plus olaparib after platinum-based chemotherapy in biomarker-selected metastatic pancreatic cancer. Link in the comments👇 #Oncology #PancreaticCancer #PrecisionOncology #Immunotherapy

We’re hiring! 🧪 The Babak Lab is looking for talented and motivated researchers to join our growing team. If you are passionate about innovative biomedical research and interdisciplinary collaboration, we would love to hear from you. Apply here: thebabaklab.com/opportunities

A phase 3 study published in @thelancet.com evaluated whether adding the gene-mediated cytotoxic immunotherapy combination of CAN-2409 and valacyclovir to standard radiotherapy could reduce this risk. Link in the comments👇 #Oncology #ProstateCancer #GeneTherapy #Radiotherapy

A new study published in @nature.com explores a new strategy for one of the most difficult colorectal cancer subtypes: BRAF-mutant CRC. Link in the comments 👇 #Oncology #ColorectalCancer #BRAF #MolecularGlue #TargetedTherapy #CancerResearch

The @fda.gov has approved Tregzi, an allogeneic regulatory T cell-based immunotherapy with HSPC and T cells, for matched donor HSCT in adults with hematologic malignancies. Link in the comments 👇 #Oncology #Hematology #StemCellTransplant #HSCT #GVHD #CellTherapy #Immunotherapy #CancerResearch

🔬 #LabLife We are happy to start building a collaboration with Tung Wah College, the first and only institution in Hong Kong offering a Bachelor’s programme in Forensic Science. Happy to be friends with you and excited for what we can explore together!

China’s NMPA has approved satricabtagene autoleucel, or satri-cel, for patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. Link in the comments 👇 #Oncology #CART #CellTherapy

🔬 #LabLife We are happy to welcome all our summer students to the lab! Wishing you a productive time and lots of new experiences! Hope you get familiar with the local culture and enjoy exploring Hong Kong ✨ #LabLife #SummerStudents #ResearchTraining #CancerResearch

A new study published in @nature.com presents a strategy for generating CAR T cells directly in vivo, using site-specific genome engineering instead of traditional ex vivo manufacturing. Link in the comments 👇 #Oncology #CART #CellTherapy #Immunotherapy #GenomeEditing

The @fda.gov has approved capivasertib in combination with abiraterone and prednisone for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Link in the comments 👇 #Oncology #ProstateCancer #PrecisionOncology #AKT #PTEN

This summer, we are excited to welcome a new group of interns to the lab! Meet Celina Xinyue Zhang and from University of Toronto, and Belikov Mikhail from Higher School of Economics. Welcome to the team! 👋 #Internship #SummerInternship #LabLife #CancerResearch

A new study published in @pnas.org explores how extrachromosomal circular DNA, or ecDNA, forms inside cancer cells and helps tumors rapidly adapt under treatment pressure. Link in the comments 👇 #Oncology #CancerResearch #ecDNA #DrugResistance #DNARepair #Glioblastoma

MajesTEC-9 is the first phase 3 study evaluating teclistamab monotherapy versus investigator’s choice of PVd or Kd in patients with relapsed or refractory multiple myeloma after 1–3 prior lines of therapy, including anti-CD38 and lenalidomide exposure. Link in the comments 👇 #Oncology

Sharing some beautiful views from Hong Kong 🇭🇰 📍 Plover Cove Reservoir Dam 📍 Hong Kong Science Park #LabLife #HongKong #ResearchLife

A new study published in @nature.com introduces prodrug-tethered lipid nanoparticles, or pLNPs, designed to co-deliver IL-12 mRNA and an IDO inhibitor prodrug directly into the tumor microenvironment. Link in the comments 👇 #Oncology #Nanomedicine #mRNA #Immunotherapy #LNP

A few weeks ago, we covered the phase 1/2 RMC-6236-001 study, where daraxonrasib showed promising activity in previously treated pancreatic cancer. Now, the phase 3 RASolute 302 trial confirms those early signals in a randomized study. Link in the comments👇 #Oncology #RAS

LARU buddies checking in! 👋 Just Kirill and Alisa sending a quick hello. Have a great weekend, everyone! 🐭💼 ​#LARU #lablife #researchbuddies #invivo

A new study published in Cancer Discovery reports the preclinical and early clinical activity of RNK08954, a highly selective and orally bioavailable KRASG12D inhibitor designed to target one of the most common KRAS mutations across solid tumors. Link in the comments 👇 #KRAS #CancerResearch

The @US_FDA has approved durvalumab (Imfinzi) in combination with Bacillus Calmette-Guerin (BCG) for adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). Link in the comments 👇 #Oncology #BladderCancer #Immunotherapy #Durvalumab

Warm welcome at the University of Palermo! 🇮🇹 Special thanks to all colleagues for making this symposium so inspiring and memorable. #AntiCancer #DrugSymposium #LabLife #CancerResearch #MetalBasedDrugs #UniversityOfPalermo

A new study published in @cellpress.bsky.social explores how cancers develop resistance to daraxonrasib, a RAS(ON) tri-complex inhibitor that works as a molecular glue by recruiting cyclophilin A to active RAS. Link in the comments 👇 #Oncology #RAS #KRAS #CancerResearch